Using MR-Linac for precise radiotherapy in cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of magnetic resonance-guided linear accelerator (MR-Linac) technology in delivering precision radiotherapy for tumors. It will analyze various outcomes including overall response rate, progression-free survival, disease control rate, overall survival, and the incidence of adverse reactions. Additionally, the study will assess the quality of life of patients using standardized measures and evaluate dosimetric parameters related to treatment. The study will involve patients aged 18-75 who have undergone imaging or treatment with MR-Linac.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients are undergoing or have undergone imaging or treatment at the MR linac;
* Age 18-75 years, male or female;
* ECOG score 0-2, life expectancy \> 6 months;
* Patients provide written informed consent.

Exclusion Criteria:

* Contraindications to MRI, such as claustrophobia and metallic or electronic implants incompatible with MRI;
* The presence of severe comorbidities that, in the opinion of the investigator, · preclude the toleration or completion of radiotherapy;
* Acute inflammatory disease requiring systemic therapy;
* The presence of active infectious disease;
* Pregnant women, nursing mothers, and patients planning to have children during the study period.

Where it's running

• The Second Affiliated Hospital of Hainan Medical University
  Haikou, China Recruiting

Study contacts

• Principal investigator: yuecan zeng, doctor — The Second Affiliated Hospital of Hainan Medical University
• Study coordinator: junnv xu, doctor
• Email: xujunnv@sina.com
• Phone: 18208946196

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ozone therapy for refractory pain and quality of life in cancer patients

  This study looks at whether adjuvant ozone therapy can improve quality of life for adults with difficult-to-treat cancer-related symptoms referred to a palliative pain unit.

  Recruiting Hospital Universitario de Gran Canaria Doctor Negrín · Las Palmas de Gran Canaria, Las Palmas · NCT07325851

• Gut microbiome in gynecologic cancer patients with pelvic toxicity

  This study looks at whether gut bacteria profiles relate to pelvic toxicity after cancer treatment and how rectal ozone therapy might affect the gut microbiome and symptoms in women with gynecologic tumors.

  Recruiting at 2 sites Hospital Universitario de Gran Canaria Doctor Negrín · Las Palmas de Gran Canaria, Las Palmas and 1 other locations · NCT07259681

• Bevacizumab plus cisplatin versus cisplatin for malignant serous effusions

  This study tests whether adding bevacizumab to intracavity cisplatin helps people with malignant serous effusions from advanced adenocarcinoma.

  Recruiting Phase 2 Qingdao Central Hospital · Qingdao, Shandong · NCT07090525

• Curative chest re‑irradiation for thoracic cancers

  This project will try a standardized high‑dose re‑radiation approach for adults with recurrent or new thoracic cancers who previously received chest radiotherapy to see how well it controls disease and what toxicities occur.

  Recruiting University of Aarhus · Aarhus, Jutland · NCT06950073

• First-line bevacizumab versus dexamethasone for symptomatic cerebral radiation necrosis after radiation for high-grade glioma or brain metastases.

  This trial will test whether first-line bevacizumab or dexamethasone works better at reducing symptoms in adults with symptomatic cerebral radiation necrosis after radiation for high-grade glioma or brain metastases.

  Recruiting at 5 sites Phase 3 The Netherlands Cancer Institute · Amsterdam and 5 other locations · NCT06888817

• Evaluating the effects of radiotherapy in pediatric and adult patients with childhood cancers

  This study looks at how radiation therapy affects both kids and adults who had childhood cancers, checking for any side effects and how well it works over time.

  Recruiting Centro di Riferimento Oncologico - Aviano · Aviano, Pordenone · NCT06639165

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.